Krebs Biochemicals and Industries Limited has informed the Exchange regarding Board meeting held on May 20, 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals reported its audited FY25 results on May 20, 2025. Revenue from operations fell to ₹4,331.19 Lacs from ₹5,042.15 Lacs in FY24, a decline of around 14%. Q4 revenue alone dropped sharply to ₹610.05 Lacs from ₹1,197.29 Lacs in the year-ago quarter. The company posted a net loss of ₹2,693.93 Lacs, wider than the ₹1,972.84 Lacs loss a year earlier, with basic EPS of ₹(12.49) versus ₹(9.15). Total expenses stayed high at ₹7,094.48 Lacs, including ₹591.42 Lacs in finance costs and ₹668.92 Lacs in depreciation. Net worth is deeply negative at ₹(14,623.89) Lacs, debt-equity ratio stands at (1.45), DSCR is (0.07), and operating cash flow turned negative at ₹(789.10) Lacs. Statutory auditor Bhavani & Co issued an unmodified opinion.
This is a deeply negative update for shareholders — losses are widening, revenue is shrinking, net worth is eroded (negative book value), debt exceeds equity, and operating cash flow has flipped negative, raising serious concerns about the company's ability to continue as a going concern. The stock is likely to face significant selling pressure, and existing shareholders face substantial risk of further value erosion.